San Diego biotechs see increased revenue

San Diego-based biotech firms have weathered the recent economic downturn by cutting both employees and underperforming drug development programs. The city's public biotechs saw their net loss increase 38 percent to $589 million, while revenue rose 49 percent to $5.8 billion from 2008 to 2009, according to a report in the San Diego Business Journal. The story appears roughly a week after Ernst & Young released a report stating the 2008/2009 economic crisis was so different, so...